Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2012) 120 (21): 357.

https://doi.org/10.1182/blood.V120.21.357.357

Published: 2012

Journal Articles

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

David A. Rizzieri, MD, Norbert Vey, MD, PhD, Xavier Thomas, MD, Françoise Huguet, Richard F Schlenk, MD, Jürgen Krauter, MD, Ph.D., Thomas Kindler, MD, Bjorn Gjertsen, MD, PhD, Igor W. Blau, Malin Johansen, Trygve Bergeland, Athos Gianella-Borradori, Tove Flem Jacobsen, Jianyu Rao, MD, Utz Krug

Blood (2012) 120 (21): 46.

https://doi.org/10.1182/blood.V120.21.46.46

Published: 2012

Journal Articles

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Blood (2012) 120 (21): 770.

https://doi.org/10.1182/blood.V120.21.770.770

Published: 2012

Journal Articles

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Blood (2012) 120 (21): 785.

https://doi.org/10.1182/blood.V120.21.785.785

Published: 2012

Journal Articles

Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220

Christoph Schaab, Dr., Felix Oppermann, Dr., Heike Pfeifer, Dr. med., Martin Klammer, Dr., Andreas Tebbe, Dr., Thomas Oellerich, Dr. med., Jürgen Krauter, Prof. Dr. med., Mark J. Levis, MD, PhD, Alexander E Perl, MD, Henrik Daub, Dr., Björn Steffen, MD, Klaus Godl, Dr., Hubert Serve, Prof. Dr. med.

Blood (2012) 120 (21): 786.

https://doi.org/10.1182/blood.V120.21.786.786

Published: 2012

Journal Articles

Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients

Felicitas Thol, MD, Britta Kölking, Iris H.I.M. Hollink, MD, PhD, Frederik Damm, MD, Marry M. van den Heuvel-Eibrink, C. Michel Zwaan, MD, PhD, Gesine Bug, Oliver G. Ottmann, MD, Katharina Wagner, MD, Michael A Morgan, PhD, Wolf-Karsten Hofmann, Gudrun Göhring, MD, Brigitte Schlegelberger, Jürgen Krauter, Prof. Dr. med., Arnold Ganser, Michael Heuser, MD

Blood (2012) 120 (21): 1402.

https://doi.org/10.1182/blood.V120.21.1402.1402

Published: 2012

Journal Articles

Expression of Roundabout Receptor 4 (Robo-4) Confers a Negative Prognosis On Patients with Acute Myeloid Leukemia

Jasmin Wellbrock, Ph.D., Eik Vettorazzi, M.Sc., Gabi Vohwinkel, M.Sc., Thoren Müller, M.D., Marianne Klokow, Carsten Bokemeyer, M.D., Ulrike Bacher, M.D., Jürgen Krauter, MD, PhD, Walter Fiedler, MD

Blood (2012) 120 (21): 1412.

https://doi.org/10.1182/blood.V120.21.1412.1412

Published: 2012

Journal Articles

Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia

Katharina Wagner, MD, Anna Both, Frederik Damm, MD, Felicitas Thol, MD, Gudrun Göhring, MD, Michael Heuser, MD, Oliver G. Ottmann, MD, Michael Lübbert, MD, Mohammed Wattad, MD, Lothar Kanz, MD, Günther Schlimok, MD, Aruna Raghavachar, MD, Walter Fiedler, MD, Hartmut Kirchner, MD, Wolfram Brugger, MD, Brigitte Schlegelberger, Gerhard Heil, MD, Arnold Ganser, Jürgen Krauter, Prof. Dr. med.

Blood (2012) 120 (21): 1381.

https://doi.org/10.1182/blood.V120.21.1381.1381

Published: 2012

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Blood (2012) 120 (21): 412.

https://doi.org/10.1182/blood.V120.21.412.412

Published: 2012

Journal Articles

Investigation of Urine/Plasma Biomarkers to Predict Tolerance and Graft-Versus-Host Disease Post Allogeneic Stem Cell Transplantation.

Christin Human, Sylvia Borchers, PhD, Michael Stadler, MD, Helmut Diedrich, Jürgen Krauter, MD, PhD, Christine Falk, Arnold Ganser, Eva M Mischak-Weissinger, MD

Blood (2012) 120 (21): 3049.

https://doi.org/10.1182/blood.V120.21.3049.3049

Published: 2012

Journal Articles

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Blood (2011) 118 (21): 80.

https://doi.org/10.1182/blood.V118.21.80.80

Published: 2011

Journal Articles

Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia

Alexander Schultze, M.D., M.Sc., Isabel Ben-Batalla, Ph.D., Michael Heuser, M.D., Kristoffer Weber, Ph.D., Robert Erdmann, Ph.D., Sacha Holland, Ph.D., Stefanie Sawall, Helena Fritz, M.Sc., Marc Tjwa, M.D., Ph.D., Thomas Schmidt, M.D., Walter Fiedler, M.D., Boris Fehse, Ph.D., Bjorn Dahlback, M.D., Klaus Pantel, M.D., Ph.D., Jürgen Krauter, Arnold Ganser, MD, Carsten Bokemeyer, M.D., Sonja Loges, M.D., Ph.D.

Blood (2011) 118 (21): 940.

https://doi.org/10.1182/blood.V118.21.940.940

Published: 2011

Journal Articles

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Jan Krönke, Lars Bullinger, Frank G. Rücker, Verena I. Gaidzik, MD, Michael WM Kühn, Karin Bezet, Veronica Teleanu, Peter Paschka, MD, Daniela Späth, Thomas Kindler, MD, Helmut R. Salih, MD, Jürgen Krauter, MD, Arnold Ganser, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Richard F. Schlenk, MD, Hartmut Döhner, MD, Konstanze Döhner

Blood (2011) 118 (21): 237.

https://doi.org/10.1182/blood.V118.21.237.237

Published: 2011

Journal Articles

Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,

Felicitas Thol, Frederik Damm, Katharina Wagner, Katarina Reinhardt, Jan-Henning Klusmann, MD, Nils von Neuhoff, Brigitte Schlegelberger, MD, Dirk Reinhardt, MD, PhD, Jürgen Krauter, Arnold Ganser, MD, Michael Heuser, M.D.

Blood (2011) 118 (21): 3548.

https://doi.org/10.1182/blood.V118.21.3548.3548

Published: 2011

Journal Articles

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

Katharina Wagner, MD, Frederik Damm, MD, Michael A Morgan, PhD, Felicitas Thol, M.D., Haiyang Yun, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Michael Heuser, M.D., Arnold Ganser, MD, Jürgen Krauter, MD

Blood (2011) 118 (21): 3554.

https://doi.org/10.1182/blood.V118.21.3554.3554

Published: 2011

Journal Articles

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

Blood (2011) 118 (21): 3558.

https://doi.org/10.1182/blood.V118.21.3558.3558

Published: 2011

Journal Articles

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

Blood (2011) 118 (21): 412.

https://doi.org/10.1182/blood.V118.21.412.412

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Richard F. Schlenk, MD, Jürgen Krauter, MD, Markus Schaich, MD, Didier Bouscary, MD, PhD, Hervé Dombret, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Anita Zahlten, PhD, Lu Wang, PhD, Oliver G. Ottmann, MD, PhD

Blood (2011) 118 (21): 423.

https://doi.org/10.1182/blood.V118.21.423.423

Published: 2011

Journal Articles

The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients

Felicitas Thol, M.D., Michael Heuser, M.D., Claudia Winschel, Frederik Damm, MD, Katharina Wagner, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Gesine Bug, Oliver G. Ottmann, MD, PhD, Wolf-Karsten Hofmann, MD, Jürgen Krauter, MD, Ph.D., Arnold Ganser, MD

Blood (2011) 118 (21): 1734.

https://doi.org/10.1182/blood.V118.21.1734.1734

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220

Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients

Expression of Roundabout Receptor 4 (Robo-4) Confers a Negative Prognosis On Patients with Acute Myeloid Leukemia

Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Investigation of Urine/Plasma Biomarkers to Predict Tolerance and Graft-Versus-Host Disease Post Allogeneic Stem Cell Transplantation.

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia

Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples

Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,

ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,

TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only